Navigation Links
Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
Date:5/27/2009

BUFFALO, N.Y., May 27 /PRNewswire/ -- Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009. The study was carried out at MD Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, the Principal Investigator from RPCI will deliver the presentation entitled "Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies."

The presentation will provide data from this multi-center Phase 1 trial that utilized the standard 3+3 design to determine the Maximum Tolerated Dose (MTD), safety, and pharmacokinetics (PK) of KX2-391 in patients with refractory solid tumors. Patients who responded to treatment will be highlighted.

This presentation was designated as Best of ASCO(R) which features high-impact abstracts from the 2009 ASCO Annual Meeting that represent the most relevant, cutting-edge science in oncology today. This information has been selected to be presented at meetings in the US and internationally because it highlights the latest scientific findings in primary disease sites and practice-changing advances in cancer prevention and treatment.

Kinex Pharmaceuticals is a drug discovery and development company that is focused on next generation drugs to treat cancer and immuno-inflammatory diseases. The Company has utilized its platform technologies to identify highly selective inhibitors of therapeutically relevant targets that are involved in signal transduction and cell cycle control.

CONTACT: Lyn Dyster, Vice President, Research Operations of Kinex Pharmaceuticals, +1-716-881-8984


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
(Date:2/10/2016)... --> --> This press release is intended for U.S. and EU ... .  --> A separate press release has been prepared for use in ... continues to strengthen its presence in Japan ... strengthen its presence in Japan   ... strengthen its presence in Japan   ...
(Date:2/10/2016)... DIEGO , Feb. 10, 2016 ... gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical company ... other chronic diseases, have entered into a Manufacturing Services ... cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in Renova,s ... --> This relationship will leverage Lonza,s expertise ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group ... associations of medical professionals throughout the country. The Guard was specifically designed to ... and procedures, employee training, regulatory updates, and compliance coaching. , In addition to ...
(Date:2/10/2016)... ... 2016 , ... Emergency rooms provide emergency care to stabilize critical health issues, ... with dental emergencies at risk of losing a tooth or their smiles. Dr. Marine ... Common dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Peyman ... is now offering a variety of comprehensive procedures for facial enhancement. The treatments ... volume restoration, lip enhancement and nasal reshaping. , As a result, patients ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of traumatic ... to conduct a survey that takes a closer look at cases of TBI being ... and causes of TBI among the aging population, and identifies the challenges associated with ...
Breaking Medicine News(10 mins):